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Background  Chronic hepatitis C is associated with significant morbidity and mor-
tality as a consequence of progression to cirrhosis, hepatocellular carcinoma, and 
liver failure. Current treatment for chronic hepatitis C with pegylated interferon (IFN) 
and ribavirin is associated with suboptimal responses and numerous adverse effects. 
A number of botanical products have been used to treat hepatic disorders. Silyma-
rin, extracted from the milk thistle plant, Silybum marianum (L) Gaertn. (Asteraceae), 
has been most widely used for various liver disorders, including chronic hepatitis C, 
B, and alcoholic liver disease. However, the safety and efficacy of silymarin have not 
been studied systematically in chronic hepatitis C.
Purpose  We describe our strategy for a phased approach for studying the impact 
of silymarin in hepatitis C, in the context of the unique challenges of botani-
cal product clinical trials and the development of specific and curative antiviral 
therapy.
Methods  This multicenter, randomized, double-masked, placebo-controlled trial 
was conducted with four clinical centers and a data-coordinating center in the 
United States, to assess the impact of silymarin therapy in patients with chronic 
hepatitis C who failed conventional antiviral therapy.
Results  Key aspects relevant to performing clinical trials of botanical products 
include early identification of an appropriate product with standard product chem-
istry, acquisition of pharmacokinetic and dosing information, selection of the appro-
priate study group, and choosing rigorous outcome variables.
Potential limitations  Trial participants were chronic hepatitis C patients who were 
nonsustained virologic responders to IFN-based therapy; therefore, the findings are 
not generalizable to all hepatitis C populations. Further, alanine aminotransferase, 
a biochemical liver test, rather than hepatitis viral RNA or liver histology was the 
primary end point.
Conclusions  The challenges identified and addressed during development of this 
United States multicenter Phase II trial to evaluate silymarin for treatment of patients 
with chronic hepatitis C infection who had failed to respond successfully to previous 
IFN-based therapy are common and must be addressed to conduct rigorous trials of 
botanical products. Clinical Trials 2012; 9: 102  –112. http://ctj.sagepub.com
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Introduction
The hepatitis C virus (HCV) is a heterogeneous 
virus; it is estimated that 170 million people are 
infected worldwide [1]. The prevalence of antibodies 
to hepatitis C in the United States is approximately 
1.6%, representing 4.1 million anti-HCV-positive 
persons, according to the National Health and 
Nutrition Examination Survey [1]. Chronic viral 
hepatitis infection can lead to cirrhosis, hepatic 
decompensation (i.e., liver failure), hepatocellular 
carcinoma (i.e., liver cancer), and death. Further, 
approximately 10,000 deaths result from hepatitis 
C-associated complications annually. End-stage 
liver disease due to chronic hepatitis C is the main 
indication for liver transplantation [2]. Current esti-
mates suggest that there will be a continually 
increasing disease burden, at least over the next 
couple of decades, from hepatitis C and its compli-
cations [2].
While there have been some advances in the 
treatment for chronic hepatitis C infection, thera-
peutic options remain limited. Over the past two 
decades, treatment has evolved from standard 
interferon (IFN) monotherapy to current standard 
of care with pegylated IFN and ribavirin [3–5]. 
Apart from less than ideal response rates for most 
HCV genotype 1 patients in the United States, 
there is a more difficult issue of tolerance of ther-
apy. Both IFN and ribavirin have numerous side 
effects that are frequently not well-tolerated by 
patients; several studies estimate that up to 86% of 
patients are deferred from conventional IFN treat-
ment due to medical or psychiatric comorbidities 
[6–8]. Substantial numbers of patients with chronic 
HCV in the United States therefore do not receive 
available therapies or are nonresponders to current 
treatment regimens, due at least in part to the ina-
bility to tolerate full therapy [3–5]. With the dearth 
of treatment options for such a common and seri-
ous disease, it is not surprising that both clinicians 
and patients have an interest in studying other 
potential therapies for treatment-resistant chronic 
HCV infection that may have a better side effect 
profile.
Silymarin, extracted from the milk thistle plant, 
Silybum marianum, is one of a variety of botanical 
products that have been used to treat hepatic disor-
ders, including chronic hepatitis C, B, and alcoholic 
liver disease [9–12]. Silymarin is primarily a mixture 
of at least six major isomeric flavonolignans and a 
few flavonoids and is touted for its antioxidant 
properties [13]. Data from the National Health 
Interview Survey (NHIS) from 2007 indicate that 
20% of the U.S. population uses botanical products 
regularly, and that silymarin use constitutes nearly 
5% of this product exposure [14].
Limitations of current silymarin data
Although largely in vitro evidence has accumulated 
on silymarin and its putative antiviral, immu-
nomodulatory, and antifibrotic properties, clinical 
studies have not suggested a clinical benefit for sily-
marin in HCV infection [9–11,15–21]. A review of 
clinical studies of botanical products, including sily-
marin, that have been used for hepatic diseases 
revealed a lack of consistency in botanical prepara-
tions, dosing, clinical outcome measures, and 
length of treatment. There was no firm evidence 
that botanical products conferred clinical benefit in 
HCV infection [9–11].
As is common with clinical trials of all or most 
botanical products, studies are limited by a lack of 
standardization of the product to be tested and lack 
of pharmacokinetic and dosing data. In addition, 
the outcome measures may not be comparable with 
those used in other studies. Furthermore, informa-
tion on duration of treatment and follow-up are 
often lacking. For clinical trials of conventional 
pharmaceuticals, extensive preliminary preclinical 
and clinical studies (i.e., pharmacokinetics, dosing, 
and mechanistic studies) are undertaken early in 
product development, prior to studies testing effi-
cacy, due to regulatory requirements of the U.S. 
Food and Drug Administration (FDA). Such data, 
however, typically are not required, or even availa-
ble, for most marketed botanical products, includ-
ing silymarin. Also, unlike conventional drugs, 
botanicals are typically mixtures of uncharacterized 
constituents; particular attention must be given to 
analyzing all potentially active ingredients. 
Therefore, it is essential to perform early-phase test-
ing of botanical products to provide such critical 
information before embarking on large-scale clini-
cal trials.
Identifying the silymarin 
manufacturer
Prior to issuing the request for applications (RFA) 
for the clinical trials of silymarin in 2005 (Figure 1), 
the U.S. National Institutes of Health (NIH), via the 
National Center for Complementary and Alternative 
Medicine (NCCAM), issued a Notice of Opportunity 
for Clinical Trial Collaboration to identify manu-
facturers of silymarin that would be interested in 
donating product and placebo for proposed future 
trials. The early identification of a manufacturer 
was essential in developing a clinical trial for this 
botanical product. Unlike conventional pharma-
ceuticals, there is considerable variability in com-
position and chemistry of marketed botanical 
products. Therefore, it was necessary to identify a 104    KR Reddy et al.
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manufacturer that could provide appropriate prod-
uct information. Moreover, as dietary supplements 
are marketed in the United States without require-
ments for standard chemistry, manufacturing and 
controls, or providing preclinical data to the FDA, 
the manufacturer selected was expected to be will-
ing to work with both NIH and FDA to provide 
such information for silymarin.
Silymarin manufacturers who responded to the 
Notice of Opportunity were requested to provide 
NIH/NCCAM information regarding their silyma-
rin product as it was anticipated that a trial of sily-
marin for a chronic liver disease would require 
approval of an Investigational New Drug (IND) 
application from the FDA; thus, product specifica-
tions would have to comply with standard FDA 
requirements. NIH/NCCAM selected the manufac-
turer based on several components of the product 
information, including product chemistry, manu-
facturing and controls, preclinical data, clinical 
data, information on regulatory filings, and the 
ability to provide support for phased clinical trials. 
Following review of responses from the manufac-
turers, the Legalon® 140 brand of silymarin mar-
keted by Rottapharm|Madaus (Monza, Italy and 
Cologne, Germany) was selected for the silymarin 
trials.
Study organization
After identifying the silymarin manufacturer, NIH/
NCCAM issued an RFA in 2005 for Phase I/II trials of 
silymarin for chronic liver disease (Figure 1) in order 
to assemble a consortium (the Silymarin in Non-
alcoholic Steatohepatitis and C Hepatitis (SyNCH) 
Study Group, Appendix). The National Institute   
of Diabetes and Digestive and Kidney Diseases 
(NIDDK) also participated in the project. This Phase 
II multicenter trial was conducted with four clinical 
centers and a data-coordinating center (DCC) in the 
United States. The steering committee for the con-
sortium comprises the principal investigators from 
the clinical centers, one of whom is the steering 
committee chair, and the DCC and two NIH project 
scientists (NIH/NCCAM and NIH/NIDDK). The 
steering committee members designed and imple-
mented the clinical trials of this consortium. A Data 
and Safety Monitoring Board (DSMB) was estab-
lished by NIH/NCCAM to provide trial oversight.
Investigational product
Legalon® 140 is a milk thistle fruit extract (Silybum 
marianum (L) Gaertn. (Asteraceae)) standardized to 
140  mg of silymarin per gelatin capsule (53% as 
total silibinin, quantified photometrically). A 
Legalon® 140 capsule contains 180  mg of dried 
extract of milk thistle fruits, or 140 mg of silymarin, 
which is the presumed active ingredient, or 108 mg 
of silymarin quantified as silibinin by high-pressure 
liquid chromatography. The total weight of the cap-
sule is 429 mg and includes other milk thistle com-
ponents of the extraction process, excipients, and 
the capsule shell. The 108 mg of silymarin in Legalon® 
capsules consists of the following potentially active 
ingredients: silibinins A + B (~50  mg), silicristin 
(~20 mg), silidianin (~15 mg), and isosilibinins A + B 
(~15  mg). The placebo gelatin capsules used in the 
trial were identically sized capsules filled with a 
powder containing lactose and other components 
of Legalon® 140, including mannitol, magnesium 
stearate, and sodium carboxymethyl starch. The 
phased trials in this program were conducted under 
an IND, held by NIH/NCCAM, from the FDA.
Figure 1.  Chronology of planning and implementation of silymarin Phase I and Phase II studies.Silymarin in chronic hepatitis C    105
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Phase I study and selection of 
doses for Phase II
In view of suggestive in vitro evidence, a phased-
study approach was developed by the SyNCH Study 
Group (Figure 1) to study the potential role of sily-
marin in research participants with chronic hepatitis 
C who were previously refractory to conventional 
therapy. Since preliminary dosing and pharmacoki-
netic data on the product were not available, a Phase 
I dose-ranging study in research participants with 
chronic HCV was performed initially by the study 
team [22]. The research participants were randomized 
to one of four silymarin doses covering a fivefold 
range (140, 280, 560 and 700  mg, thrice daily), to 
assess safety and dose–exposure relationships in HCV 
patients who were previously treatment nonrespond-
ers. No drug-related adverse events were reported 
during the Phase I study, and daily oral doses of up to 
2.1  g were well tolerated. Nonlinear pharmacokinet-
ics of silibinins A and B were noted, with data sug-
gesting that the otherwise low bioavailability of 
silymarin may be overcome at higher than usual 
doses (700  mg thrice daily). Since no adverse events 
were observed at the highest exposures obtained 
with a dose of 700 mg, this dose was identified as the 
high dose for Phase II trial, as it was expected to pro-
vide reliable exposures and to be safe and well toler-
ated in the HCV population. In addition, the dose 
burden of five pills three times daily was considered 
the largest at which acceptable patient compliance 
can be expected. As dose–exposure proportionality 
was observed over the dose range of 140–700  mg of 
silymarin, a dose of 420 mg was selected for the lower 
dose in the Phase II trial, as it would be expected to 
result in 40% lower exposure than the 700-mg dose, 
which might be associated with clinically significant 
differences in pharmacodynamic end points.
The Phase II study, the subject of this report, was 
a placebo-controlled, double-masked, randomized 
trial that focused on safety and efficacy of silymarin 
at two distinct doses (420 and 700 mg, thrice daily) 
for treating patients with chronic HCV infection 
who had previously failed to respond successfully to 
IFN-based therapy. This report describes the ration-
ale for the design of a Phase II trial of a botanical 
product in treating previous nonresponders, the 
challenges encountered in study design and imple-
mentation, and presents baseline characteristics of 
the enrolled cohort.
Methods
Selection of trial participants
This clinical trial studying silymarin treatment in 
chronic hepatitis C included treatment-resistant 
patients. Several studies estimated that up to 86% of 
patients are deferred from conventional IFN treat-
ment due to medical or psychiatric comorbidities 
[6–8]. Adverse events are common in patients with 
chronic hepatitis C treated with combination of 
pegylated IFN and ribavirin [23]. The impressive 
therapeutic response rates from Phase III clinical tri-
als of pegylated IFN and ribavirin reflect a highly 
select patient population, that is, those who are 
deemed to be ideal treatment candidates and who 
have no comorbidities that would hamper their 
ability to tolerate a rigorous therapy. The remainder 
of patients with chronic hepatitis C, those with 
absolute or relative contraindications and those 
who did not achieve sustained virological response 
with previous therapy, could potentially benefit 
from other therapies.
Thus, as conventional treatment options existed 
for chronic hepatitis C when this trial began and 
currently, this study focused on the subset who had 
failed to have a sustained virological response to 
previous IFN-based therapy (treatment resistant), 
then the standard of care, rather than treatment-
naïve patients. Lack of a sustained virological 
response was defined as detectable virus less than 6 
months following end of treatment:
1.  HCV RNA remained detectable throughout 
the therapy (nonresponders).
2.  HCV RNA dropped to below detectable levels 
during treatment but became detectable 
while still on therapy (breakthrough).
3.  HCV RNA dropped to below detectable levels 
during treatment but became detectable once 
therapy was discontinued (relapsers).
After they completed screening (see Table 1), 154 
patients with chronic hepatitis who did not have a 
sustained virological response to previous IFN-based 
antiviral therapy, with or without ribavirin, were 
allocated, using an adaptive minimization randomi-
zation scheme, to one of three treatment arms: 
420 mg of silymarin (three Legalon® capsules + two 
placebo capsules), 700 mg of silymarin (five Legalon® 
capsules), or placebo (five placebo capsules). Thus, 
five capsules of study treatment were taken orally 
thrice daily for 24 weeks. At screening, eligible 
patients were instructed to avoid the use of milk 
thistle products, and most were randomized within 
28 days.
Patients with any of the HCV genotypes were eli-
gible, provided they met the treatment-resistant 
definition. Study visits were planned as outlined in 
Figure 2; they were planned to provide the opportu-
nity to perform population-based pharmacokinetic 
studies. In addition, the multiple study visits and 
trial infrastructure provided the opportunity to 106    KR Reddy et al.
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  collect serum samples from a well-characterized 
cohort that can be assayed for mechanistic studies, 
including exploring immunologic effects of chronic 
silymarin exposure and biomarker screening.
An exemption subcommittee of the overall steer-
ing committee, comprising two hepatologists from 
the NIH/NIDDK who did not enroll participants, 
adjudicated whether participants who did not meet 
all inclusion, or who met at least one exclusion, cri-
terion could be enrolled in the trial. During accrual, 
25 exemptions were requested and 24 were 
approved. None of the exemptions were related to 
alanine aminotransferase (ALT), which was the basis 
of the primary efficacy end point of the trial.
Phase II trial objectives and 
outcome variables
The primary objectives of the Phase II trial are to 
assess the safety profile of silymarin versus placebo 
across three exposure levels (0, 420, and 700 mg) 
and to evaluate whether a 24-week course of silyma-
rin has a discernible impact on ALT, a biochemical 
marker of hepatic disease. The primary outcome 
variable for efficacy is serum ALT level of 45  IU/L 
(approximate maximum of normal range) or less, or 
a decrease in ALT from baseline level by at least 50% 
to less than 65  IU/L (approximately 1.5 times the 
upper limit of normal) at the end of the 24-week 
treatment period. The primary outcome variable for 
safety is the occurrence of a dose-limiting toxicity 
during the 24-week treatment period.
Secondary objectives of the trial include assessing 
changes in serum levels of HCV RNA during silyma-
rin therapy, characterizing the population pharma-
cokinetics and pharmacodynamics of silymarin 
isomers, including silibinins A and B, isosilibinins A 
and B, silicristin, and silidianin, following adminis-
tration of silymarin to participants with HCV, and 
exploring relationships between silymarin therapy 
and clinical markers of HCV hepatic disease activ-
ity. The relationship between dose and change in 
log10 (ALT) will also be assessed.
Choice of primary outcome 
variable
Perhaps the most direct measure of improvement in 
liver disease is obtained by assessing the grade of 
necroinflammatory activity and stage of fibrosis in 
Table 1.  Enrollment criteria for the Phase II randomized trial of silymarin for chronic hepatitis C
Enrollment criteria
Key inclusion criteria
  •  Serum HCV RNA above quantifiable level of detection by any assay after the end of previous therapy
  •  ALT ≥ 65 IU/L (i.e., approximately 1.5 times upper limit of normal) obtained during the screening period
  •  Previous treatment with any IFN-based therapy without sustained virological response
Key exclusion criteria
  •  Use of silymarin or other milk thistle preparations within 30 days prior to screening
  •    Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol, or nonprescribed complementary 
alternative medications (including dietary supplements, megadose vitamins, herbal preparations, and special teas) within 30 days 
prior to screening. A multivitamin at standard doses will be allowed
  •    Use of silymarin or other antioxidants or nonprescribed complementary alternative medications (as above) during the screening 
period or patient unwilling to refrain from taking these medications through completion of the study
  •  Any antiviral therapy within 6 months prior to screening visit
  •  Known allergy/sensitivity to milk thistle or its preparations
  •  Evidence of poorly controlled diabetes (defined as hemoglobin A1c > 8% in patients with diabetes)
  •  Lactose intolerance defined as patient reported inability to tolerate milk products
  •  Previous liver biopsy that demonstrated the presence of moderate to severe steatosis or evidence of steatohepatitis
  •  Positive test for anti-human immunodeficiency virus or hepatitis B surface antigen within 5 years of screening
  •    Average alcohol consumption of more than one drink or equivalent (>12 g) per day or more than two drinks on any 1 day over 
the 30 days prior to screening. Patients who met either criterion more than 30 days ago must have consumed a monthly average 
of 12 g or less per day of alcohol for at least 6 months prior to screening
  •    Serum creatinine level 2.0 mg/dL or greater at screening or creatinine clearance ≤ 60 cc/min or currently on dialysis. The 
creatinine clearance will be calculated according to Cockcroft–Gault
  •  Evidence of drug abuse within 6 months prior to screening or during the screening period
  •    Evidence of decompensated liver disease defined as any of the following: serum albumin < 3.2 g/dL, total bilirubin > 1.5 mg/dL, 
or protime international normalized ratio > 1.3 times normal at screening, or history or presence of ascites or encephalopathy, or 
bleeding from esophageal varices
  •  Participation in a research drug trial, exclusive of the SyNCH Phase I trial, within 6 months of enrollmentSilymarin in chronic hepatitis C    107
http://ctj.sagepub.com  Clinical Trials 2012; 9: 102 –112
paired liver biopsies obtained before and after 
  therapy [24]. Indeed, most therapeutic trials of liver 
disease have focused on liver biopsy end points. 
However, liver biopsies confer some risks and dis-
comfort to the patient and are costly to perform. 
More importantly, it is possible that significant 
changes in hepatic histology cannot be discerned in 
trials conducted for relatively short treatment peri-
ods (i.e., weeks to months). These factors, as well as 
the inherent variability of liver biopsy sampling and 
its histologic scoring, compelled the investigators to 
develop a nonbiopsy primary outcome variable for 
this Phase II trial.
Therefore, when designing this trial for resistant 
disease, the approach focused on a clinically 
important end point (changes in ALT level), which 
did not require a liver biopsy. Precedence for such 
this choice of outcome was available from earlier 
trials of antiviral therapies for chronic hepatitis C, 
prior to the advent of qualitative assays for HCV 
RNA, which utilized biochemical response (changes 
in hepatic enzyme activity) as the primary end 
point [25–29]. Histologic improvement, however, 
frequently accompanied biochemical improve-
ment in these studies during IFN therapy, even 
when sustained virological response was not 
observed. Many hepatologists consider that serum 
ALT activity may provide an indirect marker for 
improvement in disease activity, although this 
supposition has not been demonstrated conclu-
sively [3,4,29–31].
Thus, the primary outcome assessment for this 
24-week Phase II study of silymarin focuses on 
quantifying changes in ALT levels to explore initial 
evidence for efficacy of silymarin in treatment-
resistant chronic HCV infection. The primary end 
point of the trial incorporates stringent criteria for 
changes in ALT levels. In order to detect such 
marked changes in ALT, the enrollment criteria also 
required a high threshold for inclusion (at least 
65  IU/L). It is likely that therapeutic agents that 
could improve surrogate biochemical markers of 
disease activity and, perhaps, ameliorate complica-
tions of hepatic disease even without affecting HCV 
RNA, would be an attractive adjunct to currently 
available medications.
Screen Treatment-24 weeks Follow-Up
30 days 0 (BL) 2 4 6a 8 12 16a 20 24 4 12
Screening Evaluation/Criteria/Consent +
Randomization  +
Screening Demographic +
Adherence Self-Efficacy Scale  ++ ++ +
Quality of Life Questionnaires ++ ++ +
Patient Diary Summary ++ ++ ++ +
Laboratory Evaluation ++ ++ ++ ++++
Visit Evaluation ++ ++ ++++
Concomitant Medications All study visits
Adverse Event From baseline to end of study
Pharmacokinetics
1
Blood ++ +
Urine ++ +
2
Blood +++
Urine +++
Random
Blood ++ ++ ++ +
Urine ++ ++ ++ +
Whole blood for genetics sample b +
Serum and Plasma c ++ ++
a Phone interviews were conducted for weeks 6 and 16 visits.
b The genetic sample was collected at the baseline (BL) visit or at any of the subsequent study visits.
c Includes HCV RNA sample for central testing laboratory (treatment weeks 0, 12, 24, and follow-up week 4)
Figure 2.  Study visits for the Phase II trial.108    KR Reddy et al.
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Rationale for revising eligibility 
criteria to include patients with 
well-compensated cirrhosis
At initial study implementation, trial eligibility was 
restricted to patients without cirrhosis noted on any 
previous liver biopsy. Subsequently, the protocol 
was amended to permit enrollment of patients with 
well-compensated cirrhosis. This protocol change 
resulted primarily from two considerations. The 
first consideration was that a significant proportion 
of patients with chronic HCV have cirrhosis but 
were excluded from the trial. During the trial plan-
ning phase, there was considerable interest in 
including patients with well-compensated cirrhosis 
as they are a significant subgroup of those with 
chronic disease. But due to insufficient product 
safety data in the patient population, they were 
excluded. Another consideration was the lower 
than anticipated enrollment rate across all sites dur-
ing the trial enrollment phase, in part due to exclud-
ing a significant fraction of patients with chronic 
HCV infection and cirrhosis, a factor associated 
with nonresponse to IFN-based therapies.
The Phase I trial had provided safety data across 
many dose levels among HCV patients without doc-
umented cirrhosis. After the Phase II trial was initi-
ated, however, pharmacokinetic and safety data 
from a newly published study suggested that cir-
rhotic patients could be treated safely with an intra-
venous form of silibinin (Legalon® SIL). It was noted 
that circulating levels associated with the intrave-
nous form of the product were considerably higher 
than those associated with orally administered sily-
marin [12]. In that study, higher serum levels of sili-
binins A and B were achieved during daily 
intravenous infusions for a 2-week period with no 
dose-related adverse effects; patients with cirrhosis 
who had failed prior therapy were an important 
subgroup of study participants [12].
However, the safety profile observed in patients 
with cirrhosis with the intravenous form of silibinin 
(Legalon® SIL) may not be identical to silymarin since 
they are chemically two different drugs. Silymarin is 
composed of six flavonolignans including silibinins 
A and B, whereas Legalon® SIL is composed of water-
soluble hemisuccinate covalent esters of only silib-
inins A and B. Therefore, once the protocol was 
modified to include those with well-compensated 
cirrhosis, after approval from the DSMB and relevant 
institutional review boards (IRBs), the study adopted 
a more stringent plan to monitor safety in trial 
  participants with well-compensated cirrhosis. This 
plan included monitoring plasma concentrations in 
the event of a serious adverse event or hepatic bio-
chemical test elevation in someone with cirrhosis, 
since the only oral silymarin pharmacokinetic data 
published to date indicated that blood levels were 
likely to be substantially higher in cirrhotics than in 
noncirrhotics [32].
Sample size considerations
The sample size for this study was estimated based 
on the primary comparison of the proportions of 
participants in each arm who attain the primary 
end point, as defined earlier. The total sample size 
of 153 was calculated to provide 80% power to 
detect a clinically meaningful difference in outcome 
between the placebo and silymarin arms if there 
was no dose–response relationship, and over 90% if 
there was a dose–response relationship. This sample 
size calculation assumed a spontaneous ALT nor-
malization (primary end point) in 15% of placebo-
treated participants and assumed a clinically 
significant (25%) improvement in the success rate 
for the silymarin-treated group. A total of 154 par-
ticipants were enrolled.
Baseline characteristics of 
participants in the Phase II trial
The baseline characteristics of the participants 
enrolled in the Phase II trial (summarized in Table 2) 
are representative of the population of nonrespond-
ers to current hepatitis C therapy of pegylated IFN 
and ribavirin [33]. The median age of the predomi-
nantly male (71.4%) participants was 54 years. As 
anticipated, many of these previous IFN-based ther-
apy nonresponders had characteristics of difficult-
to-successfully-treat patients including genotype 1 
infection (91.4%), cirrhosis (27.9%), overweight or 
obese (85.0%), and elevated fasting blood glucose of 
at least 100  mg/dL (36.6%) [34] (Table 2). The final 
cohort is composed of 20% African-American par-
ticipants, similar to the percentage enrolled in non-
responder trials but higher than the percentage 
enrolled in clinical trials involving treatment-naïve 
patients [3–5]. Nearly 90% of the cohort reported 
regular use of medications (prescription or over-the-
counter preparations) at study enrollment, with 
almost 30% reporting taking one or more alterna-
tive or complementary medications. Dietary supple-
ments reported by 28% of trial participants at 
enrollment included a variety of products such as 
nutrients and botanicals.
Discussion
Despite a large body of literature describing the use 
of silymarin over several decades, the published 
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equivocal. Thus, it was important to systematically 
study the potential benefit of silymarin in a com-
mon chronic liver disease. The large disease burden, 
with lack of effective therapies, along with frequent 
poor tolerability of IFN and ribavirin therapy by 
chronic hepatitis C patients made them an impor-
tant group of patients in which to evaluate silyma-
rin. The previous lack of consistency across the few 
studies with regard to efficacy end points, silymarin 
preparations, and liver disease diagnosis was further 
impetus to implement a phased development plan 
for clinical testing. During the early planning stages, 
it was apparent that, as for most botanical products, 
dose-finding pharmacokinetic studies were sparse 
and doses of different preparations had been identi-
fied arbitrarily for assessment in liver diseases. In 
addition, there were no preexisting studies of botan-
ical-food or botanical-drug pharmacokinetics. It 
was also important to identify an industry collabo-
rator motivated to participate in the development 
plan, which would provide study product of stand-
ard composition and which also could provide a 
product that complied with FDA IND requirements 
for clinical testing. Implementing a phased 
approach, the investigators initially performed a 
dose-ranging Phase I study to assess pharmacokinet-
ics and safety, after which two doses of 420 and 
700  mg taken three times a day were targeted for 
evaluation in the Phase II study.
The cohort reflects the treatment-resistant HCV 
population in the United States in many ways, as it 
is predominantly male, with a number of clinical 
parameters associated with resistant disease, includ-
ing genotype 1, obesity, diabetes, and cirrhosis [3–5, 
34,35]. Several reports have suggested that African-
Americans do not respond well to hepatitis C ther-
apy [36]. Thus, it was anticipated that the cohort 
would consist of substantial numbers of African-
Americans. Although 20% of the cohort is African-
American, it is lower than might be expected in a 
cohort of treatment-resistant HCV patients. This is 
likely due to several factors, including the typically 
lower ALT levels observed in African-American 
patients, compared with Caucasian with chronic 
HCV, and the stringent inclusion threshold of at 
least 65  IU/L for the current trial [37]. In addition, 
data regarding botanical product use from the 2007 
NHIS CAM survey indicate much greater use for 
such products in Caucasians (43%) than African-
Americans (26%), suggesting that Caucasians might 
have greater interest in enrolling in studies of 
botanical therapies [14].
While IFN and ribavirin are known to cause sig-
nificant side effects, silymarin has been well tolerated 
by patients with chronic hepatitis C [9–12]. As fre-
quently noted among patients with serious chronic 
illnesses, quality of life is significantly diminished in 
patients with chronic hepatitis C. This aspect of the 
Table 2.  Baseline characteristics of the Phase II trial cohort  
(N = 154)
Patient characteristics
Men, n (%) 110 (71.4)
Race, n (%)
  White or Caucasian 114 (75.0)
  Black or African-American 31 (20.4)
 Other 9 (4.6)
Age (years)
  Median (25th percentile, 75th percentile) 54 (51, 58)
  Minimum, maximum 31, 73
Weight (kg) – male
  Mean (SD) 92.2(15.3)
  Minimum, maximum 62.5, 150.8
Weight (kg) – female
  Mean (SD) 82.6 (18.8)
  Minimum, maximum 47.3, 116.4
BMI (kg/m2) – male
  Median (25th percentile, 75th percentile) 29.1 (26.6, 32.0)
  Minimum, maximum 18.0, 48.5
 Missing 1
BMI (kg/m2) – female
  Median (25th percentile, 75th percentile) 30.0 (25.9, 34.4)
  Minimum, maximum 19.0, 43.1
Well-compensated cirrhosis, n (%) 43 (27.9)
Diabetics, n (%) 21 (13.6)
ALT (IU/L)
  Median (25th percentile, 75th percentile) 107 (83, 150)
  Minimum, maximum 60, 553
Total bilirubin (mg/dL)
  Median (25th percentile, 75th percentile) 0.8 (0.6, 1.0)
  Minimum, maximum 0.2, 1.9
HCV genotype, n (%)
 1a 54 (35.5)
 1b 21 (13.8)
  1 not otherwise specified 64 (42.1)
 2b 1 (0.7)
  2 not otherwise specified 4 (2.6)
 3a 1 (0.7)
  3 not otherwise specified 5 (3.3)
 4a 2 (1.3)
 Missing 2
HCV RNA quantitative (log10)
  Median (25th percentile, 75th percentile) 6.2 (5.8, 6.6)
  Minimum, maximum 3.8, 7.7
 Missing 2
Fasting glucose (mg/dL), n (%)
  <100 mg/dL 90 (63.4)
  ≥100 mg/dL 52 (36.6)
 Missing 12
Concomitant medications, n (%)
  No medications at baseline 20 (13.0)
  Anti-inflammatory and analgesic 
medications
52 (33.8)
  Statins and related drugs 6 (3.9)
  Vitamins/herbals/minerals 43 (27.9)
  Diabetes medications 13 (8.4)
 Antidepressants 41 (26.6)
 Other 116 (75.3)110    KR Reddy et al.
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disease is associated with considerable work absence 
due to functional disability [38]. Given the side 
effects of conventional HCV therapy, many patients 
are reluctant to adhere to standard treatment regi-
mens. Many patients explore other potential thera-
pies, such as silymarin, to complement conventional 
therapies, or less frequently, as an alternative to con-
ventional therapies. In view of the fairly widespread 
use of silymarin, the current phased investigation of 
its use in chronic hepatitis C will provide a rigorous 
assessment of its safety and associated quality of life, 
as well as further pharmacokinetic data on silymarin 
in patients with hepatic disease.
Summary
The phased-study approach undertaken for silyma-
rin as described in this report addressed several 
unique challenges to design of clinical trials pro-
grams of botanical products. As products may be 
marketed in the United States without standard 
chemistry data provided and usually with limited 
data on pharmacokinetics and dosing, much early-
phase testing is required before clinical trials can be 
designed and implemented. Unlike studies of con-
ventional pharmaceuticals, early work to identify a 
manufacturer and a standard botanical formulation 
must be undertaken to begin the process of prelimi-
nary preclinical assessment. Verifying the accepta-
bility of testing for IND filings with the FDA is an 
important early step in planning clinical testing of 
all new products for specific disease indications but 
are particularly challenging for botanical products 
due to lack of data, manufacturing requirements, 
and standard product composition. The phased-
study approach implemented by the SyNCH Study 
Group for silymarin has required several years of 
effort but has been successful in providing impor-
tant chemistry, pharmacokinetic, and dosing data 
on a commonly used botanical product. Enrollment 
in the trial began in May 2008 and concluded in 
May 2010. The treatment and follow-up phases of 
the trial were completed by March 2011.
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